Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies

Lupus

Volumn 11, Issue 11, 2002, Pages 736-743

  Shrot, S ^a   Katzav, A ^a   Korczyn, A D ^a   Litvinjuk, Y ^a   Hershenson, R ^a   Pick, C G ^a   Blank, M ^b   Zaech, J ^b   Shoenfeld, Y ^b   Sirota, P ^a   Chapman, J ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

2 glycoprotein I; Animal model; Antiphospholipid syndrome; Behavior; Memory

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; FREUND ADJUVANT; PHOSPHOLIPID ANTIBODY; BETA2 GLYCOPROTEIN 1; GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BEHAVIOR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IMMUNOPATHOLOGY; MAZE TEST; MEMORY; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANIMAL BEHAVIOR; BAGG ALBINO MOUSE; BLOOD; IMMUNOLOGY; TIME;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BEHAVIOR, ANIMAL; BETA 2-GLYCOPROTEIN I; COGNITION DISORDERS; FEMALE; GLYCOPROTEINS; IMMUNIZATION; MAZE LEARNING; MEMORY; MICE; MICE, INBRED BALB C; TIME FACTORS;

EID: 18744400496     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu255oa     Document Type: Article

References (32)

1. Hughes GRV. The antiphospholipid syndrome: Ten years on. Lancet 1993; 342: 341-344.
2. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin N Am 1997; 81: 151-177.
3. Brey RL, Escalante A. Neurological manifestations of antiphospholipid antibody syndrome. Lupus 1998; 7: S67-S74.
4. Mosek A, Yust I, Treves TA et al. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord 2000; 11: 36-38.
5. Inzelberg R, Bornstein NM, Reider I, Korczyn AD. The lupus anticoagulant and dementia in non-SLE patients. Dementia 1992; 3: 140-145.
6. Roubey RA, Hoffman M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet 1997; 350: 1491-1493.
7. Caronti B, Pittoni V, Palladini G, Valesini G. Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci 1998;156: 211-219.
8. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999; 8: 127-133.
9. Smith HR, Hansen CL, Rose R, Canoso RT. Autoimmune MRL-1pr/1pr mice are an animal model for the secondary antiphospholipid syndrome. J Rheumatol 1990; 17: 911-915.
10. Hess DC, Taormina M, Thompson J et al. Cognitive and neurologic deficits in the MRL/1pr mouse: A clinicopathologic study. J Rheumatol 1993; 20: 610-617.
11. Brey RL, Cote S, Barohn R et al. Model for the neuromuscular complications of systemic lupus erythematosus. Lupus 1995; 4: 209-212.
12. Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997; 100: 613-619.
13. Galli M, Comfurius P, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547.
14. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124.
15. Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid autoantibodies by immunization with b2 glycoprotein I (apolipoprotein H). J Clin Invest 1992; 90: 1105-1109.
16. Blank M, Faden D, Tincani A et al. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994; 7: 441-455.
17. Garcia CO, Kanbour-Shakir A, Tang H et al. Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI. Am J Reprod Immunol 1997; 37: 118-124.
18. Brey RL, Cote SA, Teale JM. Autoimmune disease is accelerated in MRL/++ mice after apolipoprotein-H immunization. Neurology 1994; 44(Suppl 2): A316.
19. Katzav A, Pick CG, Korczyn AD et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001; 10: 496-499.
20. Aron AL, Cuellar ML, Brey RL et al. Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I. Clin Exp Immunol 1995; 101: 78-81.
21. Polz E, Wurm H, Kostner GM. Investigations on beta 2-glycoprotein-I in the rat: Isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem 1980; 11: 265-270.
22. Bakimer R, Fishman P, Blank M et al. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89: 1558-1563.
23. Simiand J, Keane PE, Morre M. The staircase test in mice: A simple and efficient procedure for primary screening of anxiolytic agents. Psychopharmacology 1984; 84: 48-53.
24. Pick CG, Peter Y, Terkel J, Gavish M, Weizman R. Effect of the neuroactive steroid alpha-THDOC on staircase test behavior in mice. Psychopharmacology 1996; 128: 61-66.
25. Ordy JM, Schjeide OA. Univariate and multivariate models for evaluating long-term changes in neurobiological development, maturity and aging. Prog Brain Res 1973; 40: 25-51.
26. Schrott LM, Cmic LS. Anxiety behavior, exploratory behavior, and activity in NZB x NZW F1 hybrid mice: Role of genotype and autoimmune disease progression. Brain Behav Immun 1996; 10: 260-274.
27. Sakic B, Szechtman H, Keffer M et al. A behavioral profile of autoimmune lupus-prone MRL mice. Brain Behav Immun 1992; 6: 265-285.
28. Sakic B, Szechtman H, Denburg JA. Neurobehavioral alterations in autoimmune mice. Neurosci Biobehav Rev 1997; 21: 327-340.
29. Gray JA, McNaughton N. Comparison between the behavioural effects of septal and hippocampal lesions: A review. Neurosci Biobehav Rev 1983; 7: 119-188.
30. Farr SA, Flood JF, Morley JE. The effect of cholinergic, GABAergic, serotonergic, and glutamatergic receptor modulation on posttrial memory processing in the hippocampus. Neurobiol Learn Mem 2000; 73: 150-167.
31. Romanides AJ, Duffy P, Kalivas PW. Glutamatergic and dopaminergic afferents to the prefrontal cortex regulate spatial working memory in rats. Neuroscience 1999; 92: 97-106.
32. Shavit S, Chapman J, Abukatash M et al. Dementia in the primary antiphospholipid syndrome (PAPS) is associated with increased age, high levels of antiphospholipid antibodies and diffuse brain pathology. Neurology 1993; 43(Suppl 2): A256.